CoSTAR-HS Seed Grants
About
The Collaborative Solutions Targeting Antimicrobial Resistance Threats in Health System (CoSTAR-HS) was funded to build up capacity, infrastructure, and networking opportunities for AMR research in Singapore under the National Medical Research Council’s (NMRC’s) Centre Grant. The funding was renewed in December 2021 to build on and enhance the prior strategy that has fundamentally remained unchanged since its inception in 2017. It is a partnership involving researchers and clinicians from the National University Health System (NUHS), Singapore General Hospital (SGH), and the National Centre for Infectious Diseases (NCID). The new partner institution for the CoSTAR-HS renewal is the National University Polyclinics (NUP) – a key partner for crucial research on AMR in primary care.
This grant is designed to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of research. It is intended for innovative research projects that
- Develop and strengthen inter-institutional research collaboration or networks in Singapore
- Improve our understanding of AMR and its control in Singapore
Applicants are encouraged to tap on the facility cores developed under CoSTAR-HS, the details of which can be found here.
CoSTAR-HS Fourth Seed Grant Call (September 2023)
Application Guidelines
- Each proposal must involve investigators/researchers from 2 or more institutions, with at least 1 institution from our CoSTAR-HS partners (NUHS, SGH, NCID and NUP). Investigators and collaborators from other institutions are welcome to apply.
- Proposals are encouraged to be in line with any of the research themes within CoSTAR-HS, although research in other areas will also be considered. (Details on research themes can be found here.)
Eligibility Criteria
- PI must have a PhD and/or MBBS/BDS/PharmD/MD and/or other appropriate Postgraduate Qualifications (at least a Master’s Degree). For proposals involving patients, either the PI or co-I should be SMC-registered; or should be able to demonstrate the ability to access patients through SMC-registered collaborators. It is recognized that some studies may not require patient involvement.
- PI must hold a primary appointment in a local publicly funded institution and be salaried by the institution.
Grant Forms
The fourth grant call for proposals is open from 19th September 2023 and will close on 17th October 2023.
Application
Post-Award Management
- Grants General Administrative Guidelines
– CoSTAR-HS Terms & Conditions
- Progress Report
– PIs are required to submit a progress report 6 months from the start date.
- Final Progress Report
– PIs are required to submit a final report within 1 month after the project completion date.
- Fund Claim Form
– PIs must utilize the funding strictly for the submitted breakdown within the stipulated funding period and be accountable for all the expenses incurred. PIs should use 100% of the total approved budget before the grant end date.
- Grant Variation: Use of funds shall be subjected to NMRC guidelines and regulations. Written approval from CoSTAR-HS ARG Secretariat is required for variation of grant funding within and/or across budget categories or any other changes/amendments to the project.
- Amendment to the Research Proposal: PIs must inform CoSTAR-HS ARG Secretariat of any changes in the research proposal, such as changes in project title, protocols, etc. PIs must ensure strict adherence to the ethical guidelines and submit relevant ethics approval documents to the council if the changes involve new ethics approvals from the appropriate ethics committee.
CoSTAR-HS ARG Seed Fund Results Announcement
Congratulations to the following successful grant awardees:
FY2023 Awardees for CoSTAR-HS ARG
(Fourth Grant Call released in September 2023)
S/N
Grant Number
Project Title
Clinical Lead Principal Investigator
Host Institution
1
CoSTAR-HS/
ARGSeedGrant/2023/09
Implementation of systematic environmental surveillance and targeted environmental interventions in hospital water and sanitary fixtures to reduce hospital-acquisition of carbapenem-producing Enterobacterales
Dr Tan Thean Yen
Changi General Hospital
2
CoSTAR-HS/
ARGSeedGrant/2023/10
Preferences for primary care consultations for upper respiratory tract infection and predicted effectiveness of interventions to promote rational demand for antibiotics
Dr Elisabeth Schaffer
National University of Singapore
FY2022 Awardees for CoSTAR-HS ARG
(Third Grant Call released in March 2023)
S/N
Grant Number
Project Title
Clinical Lead Principal Investigator
Host Institution
1
CoSTAR-HS/
ARGSeedGrant/2023/06
Biofilms, the silent reservoir of multi-drug resistant Organisms (MDROs)
Dr Jyoti Somani
National University Hospital
2
CoSTAR-HS/
ARGSeedGrant/2023/07
Harnessing cell wall lipids as discriminants of antibiotic resistance and response in Gram negative bacteria
A/Prof Guan Xue Li
Nanyang Technological University
3
CoSTAR-HS/
ARGSeedGrant/2023/08
Decision trees for the management of Carbapenem-Resistant Enterobacterales (CRE) infections
A/Prof Cai Yiying
Duke-NUS Medical School
FY2022 Awardees for CoSTAR-HS ARG
(Second Grant Call released in September 2022)
S/N
Grant Number
Project Title
Clinical Lead Principal Investigator
Host Institution
1
CoSTAR-HS/
ARGSeedGrant/2022/05
Investigating the acceptance of delayed prescription among the population in Singapore: An explorative study
Prof May Oo Lwin
National University Hospital
FY2021 Awardees for CoSTAR-HS ARG
(First Grant Call released in March 2022)
S/N
Grant Number
Project Title
Clinical Lead Principal Investigator
Host Institution
1
CoSTAR-HS/ ARGSeedGrant/2022/01
PRIORUTI: PRescribing antIbiOtics in pRimary care for UTI
Dr Sky Koh Wei Chee
National University Polyclinics
2
CoSTAR-HS/ ARGSeedGrant/2022/02
Molecular epidemiology profiling of antibiotics resistance uropathogens in community-acquired UTI to improve antibiotics management
Dr Teo Teck Hui
ID Labs, Agency for Science, Technology and Research (A*STAR)
3
CoSTAR-HS/ ARGSeedGrant/2022/03
Exploring Mobile Genetic Elements (MGEs) in Carbapenem-resistant Gram-negative Bacilli
Dr Jocelyn Teo
Singapore General Hospital
4
CoSTAR-HS/ ARGSeedGrant/2022/04
Development of a clinically relevant human-associated microbiota mouse model of intestinal carbapenem-resistant Enterobacterales carriage and decolonization
Dr Ng Oon Tek
National Centre for Infectious Diseases (NCID)